Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2025 04:56 ET | Source: Research and Markets

Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - Merck, Roche, Bristol-Myers Squibb Company, Johnson & Johnson Services, and AstraZeneca Dominate

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global cancer immunotherapy...
April 29, 2025 15:30 ET | Source: Nouscom Srl

Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80%NOUS-209 is an off-the-shelf...
March 12, 2025 08:48 ET | Source: Research and Markets

Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide

Dublin, March 12, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030" report has been added to ...
January 28, 2025 11:29 ET | Source: Research and Markets

Cancer Immunotherapy Market, Valued at $125.68 Billion in 2025, Sees $194.64 Billion Opportunity by 2029 - Dominated by Amgen, AstraZeneca, Roche, Bayer, and Eli Lilly

Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report 2025" has been added to ResearchAndMarkets.com's offering.This Cancer Immunotherapy market report covers market...
January 10, 2025 04:06 ET | Source: Research and Markets

Cancer Immunotherapy Global Market Overview 2023-2030, Competitive Analysis of Amgen, AstraZeneca,Bayer, BMS, Eli Lilly, F. Hoffmann-La Roche, GSK, Immunocore, J&J, Merck, Novartis, Pfizer

Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global market for Cancer Immunotherapy...
December 26, 2024 04:13 ET | Source: Research and Markets

Cancer Immunotherapy Market Research Report 2025-2029: Curing Cancer is Generating Enormous New Markets - How Big Are They? Where is the Opportunity?

Dublin, Dec. 26, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant...
December 05, 2024 10:16 ET | Source: Research and Markets

Immuno-Oncology Strategic Industry Research Report 2023-2024 & 2030: Approval of Pembrolizumab (Keytruda) and Nivolumab (Opdivo), which Target PD-1 and PD-L1 Pathways have Set New Benchmarks

Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immuno-Oncology...
December 04, 2024 10:55 ET | Source: Research and Markets

Cancer Immunotherapy Strategic Research Business Report 2023-2030: Improved Delivery Systems, Desire for Non-Toxic Treatments, Checkpoint Inhibitors Spur New Developments and Growth

Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Cancer...
December 02, 2024 07:32 ET | Source: Research and Markets

Cancer Immunotherapy Drug Discovery Outsourcing Strategic Business Report 2024: Global Market to Reach $4 Billion by 2030, Driven by Trends in Global Expansion to Tap into Emerging Markets

Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The...
November 08, 2024 14:51 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers

Io Therapeutics, Inc., presents data on IRX5010 showing inhibition of tumor infiltrating T-cells and myeloid derived suppressor cells in multiple cancers

Next Page keyboard_arrow_right